title: Challenges, progress, and opportunities: proceedings of the filovirus medical countermeasures workshop.
abstract: On August 22-23, 2013, agencies within the United States Department of Defense (DoD) and the Department of Health and Human Services (HHS) sponsored the Filovirus Medical Countermeasures (MCMs) Workshop as an extension of the activities of the Filovirus Animal Non-clinical Group (FANG). The FANG is a federally-recognized multi-Agency group established in 2011 to coordinate and facilitate U.S. government (USG) efforts to develop filovirus MCMs. The workshop brought together government, academic and industry experts to consider the needs for filovirus MCMs and evaluate the status of the product development pipeline. This report summarizes speaker presentations and highlights progress and challenges remaining in the field.
authors.affiliation: Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. Rona.Hirschberg@verizon.net.
authors.forename: Rona
authors.initials: R
authors.lastname: Hirschberg
authors.affiliation: Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. lward@niaid.nih.gov.
authors.forename: Lucy A
authors.initials: LA
authors.lastname: Ward
authors.affiliation: Medical Countermeasure Systems, Department of Defense, Ft. Detrick, Frederick, MD 21702, USA. nicole.r.kilgore.civ@mail.mil.
authors.forename: Nicole
authors.initials: N
authors.lastname: Kilgore
authors.affiliation: Medical Countermeasure Systems, Department of Defense, Ft. Detrick, Frederick, MD 21702, USA. rebecca.kurnat.civ@mail.mil.
authors.forename: Rebecca
authors.initials: R
authors.lastname: Kurnat
authors.affiliation: Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. hschiltz@niaid.nih.gov.
authors.forename: Helen
authors.initials: H
authors.lastname: Schiltz
authors.affiliation: Biodefense Advanced Research and Development Authority, Assistant Secretary for Preparedness and Response, Department of Health and Human Services, Washington, DC 20201, USA. mark.albrecht@hhs.gov.
authors.forename: Mark T
authors.initials: MT
authors.lastname: Albrecht
authors.affiliation: Medical Countermeasure Systems, Department of Defense, Fort Belvoir, VA 22060, USA. george.w.christopher.civ@mail.mil.
authors.forename: George W
authors.initials: GW
authors.lastname: Christopher
authors.affiliation: Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. enuzum@niaid.nih.gov.
authors.forename: Ed
authors.initials: E
authors.lastname: Nuzum
mesh_terms: D000818:Animals; D057134:Antibodies, Neutralizing / Q000008:administration & dosage; D000914:Antibodies, Viral / Q000096:biosynthesis*; D016563:Filoviridae / Q000276:immunology* / Q000472:pathogenicity; D018702:Filoviridae Infections / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D006168:Guinea Pigs; D000882:Haplorhini; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D056724:Immunity, Humoral / Q000187:drug effects; D051379:Mice; D014481:United States; D059030:United States Department of Defense; D014483:United States Dept. of Health and Human Services; D019444:Vaccines, DNA; D014765:Viral Vaccines / Q000008:administration & dosage / Q000096:biosynthesis / Q000276:immunology*; D014779:Virus Replication / Q000187:drug effects
chemical_list: D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D019444:Vaccines, DNA; D014765:Viral Vaccines